March 18, 2024

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System

Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical trial to study for the Duett(TM) Vascular Graft System. This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA. During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.

Aquedeon Medical Receives FDA IDE Approval for the Duett Vascular Graft System

Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone following receipt of FDA Investigational Device Exemption (IDE) approval to conduct a staged pivotal clinical trial for its Duett Vascular Graft System in the United States. The study will be initiated in the second half of 2023, enrolling up to 20 patients at up to 5 clinical sites for the first stage of the trial.

Aquedeon Medical: Top Emerging Cardio Vascular Device Company

Aquedeon Medical was recognized by MedTech Outlook as a Top Emerging Cardiovascular Device Provider.